Loading, Please Wait...
LAS VEGAS, May 07, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand, PlusCBD Oil™ today announced that that Joseph Dowling, the Company's Chief Executive Officer, and Joerg Grasser, Chief Financial Officer, will participate in two upcoming conferences in New York, NY. These include the 2019 Canaccord Cannabis Conference, to be held May 14, 2019 and the BMO 14th Annual Farm to Market Conference to be held May 15-16, 2019.
At the 2019 Canaccord Cannabis Conference, Mr. Dowling and Mr. Grasser will meet with investors and participate in a formal presentation at 10:00am ET on Tuesday, May 14, 2019. The webcast of their presentation will be available on the Investors – News and Events section of the Company's website at https://ir.cvsciences.com/news-events and directly at http://wsw.com/webcast/canaccord34/cvsi/. The webcast will be archived for approximately 30 days.
At the BMO 14th Annual Farm to Market Conference, Mr. Dowling and Mr. Grasser will meet with investors and participate in a formal presentation on May 16, 2019.
The slide presentation to be referenced at both conferences will also be available on the Investors – News and Events section of the Company's website at https://ir.cvsciences.com/news-events.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing novel therapeutics utilizing CBD. The Company’s PlusCBD Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
Scott Van Winkle